Company intelligence / Profile preview

Molecular Templates, Inc.

Austin, Texas, USAmtem.com ↗

Ownership: Public · MTEM
Employees: ~62
Development stage: Phase 1

Overview

Molecular Templates advanced several ETB-based biologic therapeutics into Phase 1 trials. Over 100 patients were treated across programs with promising safety and efficacy signals, including deep depletion of CD38+ immune cells in myeloma and anti-tumor activity in solid tumor settings. No capillary leak syndrome was observed—a common issue with similar immunotoxins—demonstrating a favorable safety profile. The company ceased operations before advancing to later-stage trials.

Therapeutic areas: Oncology
Modalities: Engineered Toxin Bodies (ETBs)Biologics
Industry: Biotech

Drug pipeline

12 assets

evofosfamide

11 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb – collaboration to develop novel ETBs against multiple targets

Financials

Market cap: $658
Total revenue: $572K
Enterprise value: $-1.3M

Beyond the preview

Go deeper on Molecular Templates, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular Templates, Inc..

Explore the full profile